📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding ADUS

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Jim Simons Renaissance Technologies LLC	80.5K	$7.5M	0.01%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management uses terms like 'another strong quarter,' 'we achieved strong revenue growth,' and 'we continue to see favorable reimbursement support.' They express confidence in personal care trends and rate increases, but also acknowledge challenges in home health and clinical hiring with specific numbers and policy commentary. The tone is assured but detailed about both positive and negative specifics.

Q3 2025

Confident Specific

Management repeatedly used precise figures (25% revenue growth, 31.6% EBITDA increase, 6.6% same-store PCS revenue, 19% Hospice same-store) and specific future rate increases ($17.7M Texas, $17.5M Illinois). They proactively addressed hiring metrics (113 hires/day) and provided detailed margin expectations, indicating strong command of results.

Q4 2025

Confident Specific

Management uses strong, precise language: 'strong finish', 'increase of 25.6%', 'increase of 33.3%' in adjusted EBITDA, 'very pleased by the continuing growth'. They repeatedly cite specific operational and financial metrics, express optimism on regulatory and hiring trends, and frame challenges as temporary or manageable.

Q1 2026 latest

Confident Specific

Management repeatedly used phrases like 'solid start', 'consistently deliver growth', 'very pleased', 'strong cash flow', and provided specific figures such as revenue +7.7% and adjusted EPS +14.1%, projecting assurance in their strategy.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis strengthens after this call. Addus demonstrated consistent revenue and earnings growth, strong cash flow ($52.4M operating cash), and a clean balance sheet (net cash position after paying down debt). The entry into Indiana provides a new growth market with favorable rate dynamics, and the caregiver app rollout across large states should improve service percentage and caregiver retention. Management signaled a more active M&A pipeline, including larger deals, which could accelerate scale. Key items to watch next quarter: personal care census trajectory (especially Illinois turning to growth), progress of the Indiana acquisitions and integration, any further state rate increases (e.g., New Mexico funding allocation, Illinois budget), and home health recovery toward year-over-year growth. The call reinforces that Addus is well-positioned to benefit from industry tailwinds and consolidate fragmented personal care markets.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Addus HomeCare Q1 2026 revenue $363.6M (+7.7%), adj. EPS $1.62 (+14.1%), 77% personal care.

Revenue & Profitability

Q1 2026 revenue was $363.6 million, up 7.7% from $337.7 million in Q1 2025. Adjusted EBITDA was $44.5 million (+9.7%). Adjusted net income per diluted share was $1.62, up from $1.42. Cash from operations was $52.4 million, and cash on hand was $103.1 million.

Outlook

Management sees favorable demographics driving demand for home-based care. State rate support continues, including a 3.9% increase in Illinois effective Jan 1, 2026, and potential additional funding from New Mexico. The CMS 80/20 Medicaid Access Rule is expected to be eliminated, which is viewed positively for the industry.

Growth Drivers

Key growth drivers include personal care same-store revenue growth of 6.5% (led by Illinois), hospice same-store revenue growth of 7.7% with ADC up 8.2%, the expansion into Indiana via two acquisitions (HomeCourt Home Care and a pending deal), and the caregiver app improving fill rates.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

Gross margin was 31.9% in Q1 2026, consistent with prior year. Adjusted G&A improved to 19.6% of revenue from 19.9%. Adjusted EBITDA margin was 12.2% versus 12.0%, and management expects the full-year adjusted EBITDA margin to remain above 12%. Seasonal payroll tax resets and merit increases were noted.

Key Risks

Risks flagged include weather-related revenue loss ($1.5 million in Q1), potential census softness (though Illinois showed improvement), and uncertainty in home health rate environment. The 80/20 rule elimination is expected but not yet finalized. Hospice cap risk is not a current concern.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-04

Revenue grew 8% year-over-year to $377.4M, with adjusted EPS up 16% and adjusted EBITDA up 12%. Personal care and hospice segments drove growth, while home health showed sequential improvement. Strong cash flow and reduced debt support ongoing acquisitions and expansion.

Q1 2026 Q1 2026 2026-05-05

Revenue grew 7.7% to $363.6M in Q1 2026, with adjusted EPS up 14.1% and strong cash flow supporting debt reduction and M&A. Personal care and hospice segments drove growth, aided by rate increases and operational improvements.

Q4 2025 Q4 2025 2026-02-24

Fourth quarter and full-year 2025 saw strong revenue and EBITDA growth, driven by organic expansion, acquisitions, and favorable rate increases in key states. Personal Care and Hospice segments outperformed, while Home Health faced headwinds but showed signs of improvement.

Q3 2025 Q3 2025 2025-11-04

Third quarter 2025 saw 25% revenue growth and 31.6% higher Adjusted EBITDA, driven by strong Personal Care and Hospice performance, recent acquisitions, and favorable state rate increases. Gross margin and cash flow improved, with continued momentum expected into Q4 and 2026.

Q2 2025 Q2 2025 2025-08-05

Second quarter 2025 saw 21.8% revenue growth and 24.5% higher adjusted EBITDA, driven by strong personal care and hospice performance, strategic acquisitions, and favorable state reimbursement trends. Margin expansion and further growth are expected, despite regulatory and labor headwinds.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.